The CRO Clinilabs has announced the expansion of its European operations, including the establishment of the company's European Union headquarters at Switzerland Innovation Park Basel Area and the appointment of Dr Anne-Marie Nagy as Executive Vice President and Head of Clinilabs Europe.
Switzerland Innovation Park Basel Area is part of Switzerland's national innovation network and is located within the globally recognised life sciences cluster of the Basel region, uniting biopharma companies, research institutions and clinical innovation leaders.
"Europe is a critical pillar of Clinilabs' long-term growth strategy," said Dr Gary K. Zammit, President and CEO of Clinilabs.
Establishing our EU headquarters positions us within one of the world's most concentrated life sciences ecosystems.
"Combined with Dr Nagy's leadership, this expansion enhances our ability to serve European sponsors with senior-level engagement and localised leadership, increasing our ability to support European clinical programmes and meet regional regulatory requirements."
Dr Nagy brings more than 25 years of global experience in clinical drug development, operational strategy and P&L
leadership across pharmaceutical and CRO organisations.
The company stated that she will lead Clinilabs' European growth strategy, oversee EU financial performance and direct cross-functional teams to deliver operational excellence and sustainable profitability.
"I am excited to lead Clinilabs' European organisation during this important phase of growth," said Dr Nagy.
The choice for our EU headquarters positions Clinilabs at the centre of a highly collaborative and scientifically advanced environment.
"I look forward to expanding our European footprint and delivering exceptional value to our clients."
The expansion in Europe aligns with Clinilabs' global strategy to enhance its capabilities focused on CNS while preserving its "niche, high-touch operating model."
The company added that additional investments will be announced in the upcoming months.